Upside | ||||||
|---|---|---|---|---|---|---|
| ARGX | 5.31% | aa.aa | 965.53 | -0.62% | 637 | |
| KYMR | 4.91% | aa.aa | 136.17 | -0.34% | 4,083 | |
| KOD | 3.02% | aa.aa | 108.11 | +0.05% | 3,259 | |
| MRNA | 2.60% | aa.aa | 247.51 | -1.32% | 1,116 | |
| INSM | 2.58% | aa.aa | 117.71 | -1.49% | 2,567 | |
| PCVX | 2.35% | aa.aa | 66.85 | +0.73% | 4,017 | |
| RVMD | 2.27% | aa.aa | 192.15 | -0.47% | 1,307 | |
| RYTM | 2.22% | aa.aa | 113.72 | -0.20% | 2,246 | |
| PRAX | 2.17% | aa.aa | 340.48 | +0.85% | 753 | |
| SYRE | 2.14% | aa.aa | 105.06 | +0.55% | 2,267 |
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Biotech ETF is an exchange traded fund launched and managed by T. Rowe Price Associates, Inc. It invests in public equity markets of the United States. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth stocks of companies across diversified market capitalization. It employs fundamental analysis with bottom-up and top-down stock picking approach to create its portfolio. T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Biotech ETF was formed on September 16, 2026 and is domiciled in the United States.